December 2, 2022 —  The U.S. Senate today passed the bipartisan Cardiovascular Advances in Research and Opportunities Legacy (CAROL) Act, which will prioritize research on valvular heart disease. The bill now heads back to the House of Representatives for a final vote. An earlier version of the bill passed the House unanimously last December. 

Nancy Brown, chief executive of the American Heart Association, a global force for healthier lives for all, issued the following statement: 

New York Cardiovascular Symposium 2022

December 1, 2022 —  Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) have identified a new therapeutic target for the prevention of heart failure linked to aortic stenosis. The study was led by Dr. Borja Ibáñez, Clinical Research Director at the CNIC, cardiologist at Hospital Universitario Fundación Jiménez Díaz, and member of the Spanish cardiovascular research network (CiberCV).

December 1, 2022 —  A new method for determining whether patients with heart disease need coronary stents or bypass surgery is more effective than the angiogram, which is currently used, according to research from UTHealth Houston Heart & Vascular. 

November 30, 2022 — The Smidt Heart Institute at Cedars-Sinai has selected board-certified cardiothoracic surgeon 

November 30, 2022 — Boston Scientific Corporation has announced the first results from the ACURATE neo2 Post Market Clinical Follow-up (PMCF) study evaluating the performance of the ACURATE neo2TM Aortic Valve System.

November 30, 2022 — Medtronic’s newest generation self-expanding, transcatheter aortic valve replacement (TAVR) system, Evolut FX, significantly improved commissure alignment during TAVR procedures compared to earlier generation Evolut systems. A late breaker presentation at PCR London Valves 2022 summarized the early limited market release experience with the Evolut FX system in 168 patients from six US centers.

November 29, 2022 — Researchers have developed a deep learning model that uses a single chest X-ray to predict the 10-year risk of death from a heart attack or stroke, stemming from atherosclerotic cardiovascular disease.

November 28, 2022 – Tenaya Therapeutics, a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for its second gene therapy product candidate, TN-401, for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now